Page 6 of 21
EN4.32 | Acute and Chronic Sinusitis with Complications — SDL Guide (Part 3)
Self-Assessment: Sinusitis and Its Complications
Work through these clinical scenarios to test your reasoning on sinusitis diagnosis and complication management before tackling the final self-check questions.
Scenario 1: A 25-year-old woman presents with 7 days of bilateral nasal congestion, clear nasal discharge, and mild facial pressure following a viral URTI. She has no fever, her discharge has become slightly yellow over the last 2 days, and she feels she is beginning to improve. Should she receive antibiotics?
Expected answer: No. She is improving, her symptoms have not crossed 10 days, and the yellow discharge alone does not indicate bacterial ARS (colour of discharge is a poor predictor of bacterial infection). Management is symptomatic — saline irrigation, analgesics, topical decongestant (short-term), and reassurance that most ARS resolves within 7–10 days without antibiotics. Prescribing antibiotics here contributes to antibiotic resistance without clinical benefit.
Scenario 2: A 35-year-old diabetic patient presents with severe unilateral right nasal pain, blackish crusting in the right nasal cavity, and fever of 39°C. Anterior rhinoscopy shows grey-black necrotic mucosa in the right nasal cavity. CT scan shows right maxillary and ethmoid opacification with bony erosion.
Expected answer: This is invasive fungal rhinosinusitis (mucormycosis) in a diabetic patient. The black necrotic mucosa, diabetic ketoacidosis risk, and bone erosion on CT are classic. This is a medical and surgical emergency — broad-spectrum antifungal therapy (liposomal amphotericin B), urgent surgical debridement of necrotic tissue, aggressive diabetic control. Mucormycosis has a very high mortality if not recognised and treated rapidly.
Scenario 3: During a tutorial, a faculty member asks you the difference between macrolide use in CRSwNP and CRSsNP. What is your answer?
Expected answer: Macrolide antibiotics (azithromycin, clarithromycin) at low anti-inflammatory doses are recommended for CRSsNP (without polyps) — they exert immunomodulatory effects on neutrophilic inflammation independent of their antibiotic action. They are NOT recommended for CRSwNP (with polyps) — the eosinophilic type 2 inflammation of CRSwNP does not respond to macrolide immunomodulation; corticosteroids and biologics are the appropriate anti-eosinophilic agents here. Confusing these two CRS phenotypes is a common error in examinations.
SELF-CHECK
A 14-year-old boy with a 4-week history of purulent nasal discharge and frontal headache is found on CT to have bilateral maxillary and ethmoid sinusitis. He has not improved on two courses of oral amoxicillin. His mother asks whether he needs an operation. The most appropriate next step according to stepwise management of CRS is:
A. Proceed immediately to FESS as first-line treatment for children with CRS
B. Prescribe 12 weeks of topical intranasal corticosteroid spray and saline nasal irrigation before considering surgery
C. Switch to IV antibiotics and admit to hospital
D. Add montelukast and antihistamines and review in 2 weeks
Reveal Answer
Answer: B. Prescribe 12 weeks of topical intranasal corticosteroid spray and saline nasal irrigation before considering surgery
Stepwise management of CRS (EPOS 2020) mandates a full trial of adequate medical therapy — topical intranasal corticosteroids + saline nasal irrigation for at least 12 weeks — before surgery is considered. Two courses of antibiotics alone is not adequate CRS treatment; antibiotics address secondary bacterial component but do not treat the underlying mucosal inflammation. FESS is reserved for CRS that is refractory to optimal medical therapy. IV antibiotics are not indicated for uncomplicated CRS (no orbital or intracranial complication). Montelukast and antihistamines are adjuncts when there is significant allergic rhinitis, not the primary step in CRS management without polyps.